Inhibikase Therapeutics (IKT)
NASDAQ:IKT
US Market

Inhibikase Therapeutics (IKT) Technical Analysis

Compare
167 Followers

Technical Sentiment

Overall Consensus
Strong Sell
0Bullish
0Neutral
13Bearish
Technical Analysis Consensus
Strong Sell
0Bullish
0Neutral
1Bearish
Moving Average Consensus
Strong Sell
0Bullish
0Neutral
12Bearish
Inhibikase Therapeutics’s (IKT) Moving Averages Convergence Divergence (MACD) indicator is -0.05, suggesting Inhibikase Therapeutics is a Buy.
Inhibikase Therapeutics’s (IKT) 20-Day exponential moving average is 2.22, while Inhibikase Therapeutics’s (IKT) share price is $1.84, making it a Sell.
Inhibikase Therapeutics’s (IKT) 50-Day exponential moving average is 2.36, while Inhibikase Therapeutics’s (IKT) share price is $1.84, making it a Sell.

Inhibikase Therapeutics (IKT) Pivot Points

Apr 06, 2025, 04:34 AM
Name
S3
S2
S1
Pivot Points
R1
R2
R3
Classic
1.92
2.03
2.11
2.22
2.30
2.41
2.49
Fibonacci
2.03
2.10
2.15
2.22
2.29
2.34
2.41
Pivot points are a technical analysis tool used by traders to identify potential support and resistance levels in financial markets. Pivot points are calculated based on the previous day's high, low, and close prices, and are used to help traders identify levels at which the price may reverse or continue to trend.

Inhibikase Therapeutics (IKT) Moving Averages

Apr 06, 2025, 04:34 AM
Period
Simple
Exponential
MA5
2.06Sell
2.04Sell
MA10
2.21Sell
2.14Sell
MA20
2.25Sell
2.22Sell
MA50
2.36Sell
2.36Sell
MA100
2.62Sell
2.38Sell
MA200
2.08Sell
2.09Sell
Inhibikase Therapeutics’s (IKT) 10-Day exponential moving average is 2.14, while Inhibikase Therapeutics’s (IKT) share price is $1.84, making it a Sell.
Inhibikase Therapeutics’s (IKT) 100-Day exponential moving average is 2.38, while Inhibikase Therapeutics’s (IKT) share price is $1.84, making it a Sell.
Inhibikase Therapeutics’s (IKT) stock price is $1.84 and Inhibikase Therapeutics’s (IKT) 50-day simple moving average is 2.36, creating a Sell signal.
Inhibikase Therapeutics’s (IKT) stock price is $1.84 and Inhibikase Therapeutics’s (IKT) 100-day simple moving average is 2.62, creating a Sell signal.
Inhibikase Therapeutics’s (IKT) stock price is $1.84 and Inhibikase Therapeutics’s (IKT) 200-day simple moving average is 2.08, creating a Sell signal.

Inhibikase Therapeutics (IKT) Technical Indicators

Apr 06, 2025, 04:34 AM
Name
Value
Implied Action
RSI (14)
38.54
Neutral
STOCH (9,6)
15.32
Buy
STOCHRSI (14)
29.20
Neutral
MACD (12,26)
-0.05
Buy
ADX (14)
10.96
Buy
Williams %R
-89.09
Buy
CCI (14)
-87.88
Neutral
ATR (14)
0.20
-
Ultimate Oscillator
44.58
Neutral
ROC
-22.03
Sell
Inhibikase Therapeutics’s (IKT) Relative Strength Index (RSI) is 38.54, creating a Neutral signal.
Inhibikase Therapeutics’s (IKT) Trend Strength Indicator (ADX) is 10.96, creating a Buy signal.
Inhibikase Therapeutics’s (IKT) Commodity Channel Index (CCI) is -87.88, creating a Neutral signal.
Inhibikase Therapeutics’s (IKT) Price Rate of Change (ROC) is -22.03, creating a Sell signal.

FAQ

Is IKT a Buy, Hold, or Sell?
Based on IKT’s technical indicators, IKT is a Strong Sell.
    What is IKT’s RSI (14)?
    IKT’s RSI (14) is 38.54, which suggests IKT is a Neutral.
      What is IKT’s MACD?
      IKT’s MACD is -0.05, which suggests IKT is a Buy.
        What is IKT’s 5-day moving average?
        IKT’s 5-day moving average is 2.06, which suggests IKT is a Sell.
          What is IKT’s 20-day moving average?
          IKT 20-day moving average is 2.25, which suggests IKT is a Sell.
            What is IKT’s 50-day moving average?
            IKT’s 50-day moving average is 2.36, which suggests IKT is a Sell.
              What is IKT’s 200-day moving average?
              IKT’s 200-day moving average is 2.08, which suggests IKT is a Sell.
                What is IKT’s Williams % R (14)?
                IKT’s Williams % R (14) is -89.09, which suggests IKT is a Buy.
                  What is IKT’s CCI (14)?
                  IKT’s CCI (14) is -87.88, which suggests IKT is a Neutral.
                    What am I Missing?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis